<DOC>
	<DOCNO>NCT02263131</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity IL-YANG Inactivated Split Influenza Vaccine ( IL-YANG FLU Vaccine Prefilled Syringe INJ . ) administer single intramuscular injection .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Immunogenicity Safety Inactivated Split Influenza Vaccine Healthy Korea Children</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , active-controlled study . Before initiation protocol-specific activity , write informed consent obtain patient legally acceptable representative ( consent legally acceptable representative require child young 10 year age , site , child young 7 year age ) . Subjects met eligibility criterion screen assessment specify protocol , randomized test group comparator group ratio 5 1 accord pre-generated site-specific randomization table , receive single dose two dos study vaccine . The investigator perform efficacy ( immunogenicity ) safety assessment throughout study . Efficacy data collect Visit 1 ( prior vaccination ) end-of-study visit efficacy ( immunogenicity ) assessment , safety assessment , subject legally acceptable representative instruct record treatment-emergent adverse event Patient Diary card . For randomized subject , blood sample obtain prior vaccination , study vaccine 0.5mL 0.25mL administer deltoid muscle anterolateral thigh muscle . For child age 6 month &lt; 9 year age previously expose influenza virus previously receive influenza vaccine , another dose study vaccine administer 4 5 week first dose . Blood sample collect 4 5 week last dose study drug assessment antibody titer . All subject follow 6 month last dose study drug safety assessment , Month 6 follow-up visit end-of-study visit .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy men woman age 6 month &lt; 18 year Subjects bear full term pregnancy ( 37 week ) Voluntary write informed consent obtain subject subject 's legally acceptable representative ( consent legally acceptable representative require subject young 10 year age ( subject younger 7 year age institution ) ) . Subject know allergy egg , chicken , neomycin , gentamicin component study vaccine Subject receive influenza vaccine within last 6 month Subject , family history , immune system disorder include immune deficiency disease Subject history GuillainBarre syndrome Subject Down 's syndrome cytogenetic disorder . Subject severe chronic disease investigator 's opinion would make subject good candidate clinical trial Subject hemophilia treat anticoagulant , increased risk serious bleed intramuscular injection Subject acute fever body temperature &gt; 38.0 CÂº within 72 hour prior administration study vaccine Subject previously receive another vaccine within 28 day administration study drug , schedule receive another vaccine study period . Subject receive immunosuppressant immune modify drug within last 3 month prior administration study vaccine Subject previously receive immunoglobulin bloodderived product within last 3 month prior administration study vaccine , expect treat immunoglobulin bloodderived product study . Subject participate another experimental study within 30 day prior administration study vaccine Subject clinically significant medical psychological condition investigator 's opinion would suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Split influenza vaccine</keyword>
	<keyword>Seasonal influenza vaccine</keyword>
</DOC>